Amplia Therapeutics Ltd. (AU:ATX) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Amplia Therapeutics Limited has reported a significant 149% increase in losses for the half-year ending September 2024, totaling $2.8 million, while revenues fell by 41% to approximately $1.5 million. Despite these challenges, the company remains focused on developing its pipeline of Focal Adhesion Kinase inhibitors for cancer and fibrosis, with no dividends declared for the period.
For further insights into AU:ATX stock, check out TipRanks’ Stock Analysis page.